← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Strang Cancer Prevention Center
New York, NY
$7,537,857
Total funding
10
Grants
Funding over time
peak $2.7M · FY2005–10$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$9,581,576 · 11
By mechanism
N01$6,528,221 · 7
P30$2,043,719 · 1
R01$535,430 · 1
R21$281,806 · 1
R03$192,400 · 1
Investigators at Strang Cancer Prevention Center
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
In Vitro and In Vivo screening of chemopreventive agents$2,702,092
N01 · FY2010 · CA
PHASE II CLINICAL TRIAL OF CELECOXIB (OR NSAID)$1,918,721
N01 · FY2000 · CN
Cooperative Core Lab and Clinical Nutrition Research$815,374
P30 · FY2006 · CA
Cooperative Core Lab and Clinical Nutrition Research$805,840
P30 · FY2005 · CA
EVALUATION OF INTERMEDIATE ENDPOINTS AND THEIR MODULATIO$610,578
N01 · FY2000 · CN
MECHANISM-BASED IN VITRO SCREENING OF CHEMOPREVENTIVE AG$497,962
N01 · FY2000 · CN
Cooperative Core Lab and Clinical Nutrition Research$422,505
P30 · FY2004 · CA
IN VITRO SCREENING OF CHEMOPREVENTIVE AGENTS THAT INHIBI$349,968
N01 · FY2000 · CN
EFFECTS OF FOLATE-DEFICIENT WESTERN-STYLE ON TRANSGENIC$293,632
N01 · FY2000 · CN
FUNCTIONAL ANALYSIS OF BRCA1 MUTANTS$267,715
R01 · FY2002 · CA
FUNCTIONAL ANALYSIS OF BRCA1 MUTANTS$267,715
R01 · FY2003 · CA
INTERMEDIATE BIOMARKERS FOR COLORECTAL CANCER &MELANOMA$155,268
N01 · FY2000 · CN
INTERNATIONAL CENTERS AGAINST ORAL CANCER$140,903
R21 · FY2001 · DE
INTERNATIONAL CENTERS AGAINST ORAL CANCER$140,903
R21 · FY2000 · DE
Inhibiting Survivin for Chemoprevention of Colon Cancer$98,100
R03 · FY2004 · CA
Inhibiting Survivin for Chemoprevention of Colon Cancer$94,300
R03 · FY2005 · CA